9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma

ConditionPleural Mesothelioma|Malignant Pleural MesotheliomaEstimated Enrollment: 70Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 99-124Study First Received: September 12, 2005Last Updated: March 26, 2014Estimated Primary Completion Date: April 2002Primary Outcome Measures:To determine the maximally tolerated dose of intracavitary cisplatin in patients with malignant pleural mesothelioma,|To quantitate the safety of intraoperative intrathoracic/intraperitoneal hyperthermic cisplatin|to study the pharmacokinetics of cisplatin administered in this way.Sponsors and Collaborators:Dana-Farber Cancer Institute|Brigham and Women's HospitalResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00165555...

Continue reading

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 17Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: I207Study First Received: December 1, 2011Last Updated: September 16, 2016Estimated Primary Completion Date: April 2014Primary Outcome Measures:Response Rate|Amount and severity of adverse events|Duration of Response|Blood and tissue marker evaluationSponsors and Collaborators:NCIC Clinical Trials Group|Canadian Cancer Trials GroupResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01486368...

Continue reading

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 89Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: MORAb-009-003 AmatuximabStudy First Received: August 19, 2008Last Updated: November 13, 2015Estimated Primary Completion Date: June 2011Primary Outcome Measures:Progression free survival using the EORTC modified RECIST criteria.|Overall response, duration of survival, overall survival and safety.Sponsors and Collaborators:MorphotekResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00738582...

Continue reading

Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma

ConditionMalignant Mesothelioma|Perioperative/Postoperative ComplicationsEstimated Enrollment: 44Age Group: Child, Adult, SeniorGender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: CDR0000068155|CRC-BOC-L52|EU-20033Study First Received: September 11, 2000Last Updated: December 18, 2013Estimated Primary Completion Date: nullPrimary Outcome Measures:Incidence of metastatic skin nodulesSponsors and Collaborators:University of Glasgow|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00006231...

Continue reading

Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 32Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: NL25655.031.08Study First Received: September 27, 2010Last Updated: February 27, 2017Estimated Primary Completion Date: November 13, 2012Primary Outcome Measures:To test the impact of the addition of axitinib to standaard chemotherapy treatment on histology samples|the side effects of the standard chemotherapy and the additional risks related to axitinib useSponsors and Collaborators:The Netherlands Cancer Institute|PfizerResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01211275...

Continue reading

Capecitabine in Treating Patients With Malignant Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 27Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CALGB-39807|U10CA031946|CLB-39807|CDR0000067422Study First Received: January 21, 2000Last Updated: July 12, 2016Estimated Primary Completion Date: December 2003Primary Outcome Measures:Sponsors and Collaborators:Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00004183...

Continue reading

Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 59Age Group: up to 69 Years   (Child, Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Primary Purpose: TreatmentStudy ID Numbers: EORTC-08031|2004-004273-28Study First Received: September 26, 2005Last Updated: July 17, 2012Estimated Primary Completion Date: August 2007Primary Outcome Measures:Feasibility in terms of 90-day progression-free survival|Toxicity|Progression-free survival|Overall survivalSponsors and Collaborators:European Organisation for Research and Treatment of Cancer - EORTCResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00227630...

Continue reading

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

ConditionMalignant MesotheliomaEstimated Enrollment: 61Age Group: 18 Years to 120 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CDR0000616162|S0722|U10CA032102Study First Received: October 8, 2008Last Updated: January 10, 2017Estimated Primary Completion Date: April 2014Primary Outcome Measures:Progression-Free Survival|Response|Overall Survival|Frequency and Severity of ToxicitiesSponsors and Collaborators:Southwest Oncology Group|National Cancer Institute (NCI)Result Received: October 26, 2016Website Link: https://ClinicalTrials.gov/show/NCT00770120...

Continue reading

Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

ConditionMalignant Mesothelioma|Pulmonary ComplicationsEstimated Enrollment: 494Age Group: 25 Years to 80 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case Control|Time Perspective: ProspectiveStudy ID Numbers: CDR0000518348|P30CA022453|WSU-2006-057|WSU-HIC-094806MP2FStudy First Received: May 9, 2009Last Updated: March 4, 2014Estimated Primary Completion Date: March 2013Primary Outcome Measures:Identification of potential drug targets for therapeutic strategies to treat asbestos fiber-related diseasesSponsors and Collaborators:Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00897247...

Continue reading

Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 30Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: VS-6063-203Study First Received: December 2, 2013Last Updated: February 1, 2017Estimated Primary Completion Date: January 2017Primary Outcome Measures:Assess biomarker responses to VS-6063 in tumor tissue|Evaluate the safety of VS-6063 (defactinib)|Evaluate the pharmacokinetics of VS-6063 (defactinib)|To evaluate the tumor response to VS-6063 (defactinib)Sponsors and Collaborators:Verastem, Inc.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02004028...

Continue reading